4상모집 중단 (진행 중)

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

연구 개요

Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase.

스폰서
협력: 일라이 릴리
적응증
Systemic Sclerosis
중재
Baricitinib, Cyclophosphamide
목표 등록
60
시작일
2022-03-08
완료(예정)
2026-11-12

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.